Eli Lilly’s Zepbound is helping to solve one of the most intractable health challenges of our time: Obesity. Now, the drugmaker hopes to crack another significant public health problem: Sleep disorders. https://t.co/olBNCxJHzK ...

Shares of Centessa Pharmaceuticals (CNTA +43.80%) surged on Tuesday after the drugmaker struck a deal to be acquired by Eli Lilly (LLY +3.55%) for as much as $7.8 billion. An enticing offer for Centessa's investorsUnder the terms of the deal, Lilly would purchase Centessa for $38 per share in cash. That's a premium of nearly 38% to the healthcare stock's closing price on Monday.Centessa's shareholders would also receive a non-transferrable contingent value right, which could be valued at up to $9 per share ...

Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Compl ...

Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025.Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday.Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake during the day. The drugs may also be used to treat other neuro ...

For stock investors, any beaten-down sector is worth combing through for bargains. These days, healthcare certainly qualifies; the S&P Composite 1500 Health Care index has ticked only marginally higher over the past year, against the nearly 12% growth of the broader, multisector S&P 500 index. There are more than a few discount healthcare stocks with potential. Here's a look at a pair that certain analysts believe could rise by at least 60% over the coming year -- Viking Therapeutics (NASDAQ: VKTX) and H ...

Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab LONDON, March 31 (Reuters) - Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients payin ...

Eli Lilly (NYSE: LLY) is a leading healthcare company that has been generating some incredible results in recent years. It has some excellent GLP-1 drugs in its portfolio -- Zepbound and Mounjaro -- which are in high demand from patients looking to lose weight and become healthier. The knock on the stock these days, however, is that it may have gotten too expensive, and that demand may also slow down in the future. As a result, shares of Eli Lilly haven't been all that hot of late. Instead, they've been in ...

Core Insights - Eli Lilly is significantly enhancing its commitment to AI-driven drug development through an expanded partnership with Insilico Medicine, indicating a strong belief in the potential of AI technology in pharmaceuticals [2][3]. Group 1: Partnership Details - Eli Lilly is expanding its collaboration with Insilico Medicine, granting an exclusive license to market any drugs developed through this partnership [2]. - The deal includes an upfront payment of $115 million, with potential milestones that could increase the total value to $2.75 billion [4]. - This partnership builds on previous collaborations, including a software licensing agreement initiated in 2023 and a research collaboration worth over $100 million established last November [4]. Group 2: AI Drug Development - Insilico Medicine has developed 28 drugs using AI, with approximately half currently in clinical trials [4]. - The AI tools developed by Insilico are utilized in Canada and the Middle East, with early clinical development conducted in China [4]. Group 3: Market Reaction - Eli Lilly's stock has experienced a decline of nearly 20% since the beginning of the year, despite a slight increase of about 1% in early trading following the announcement of the partnership [6].

Core Insights - Bristol Gate Capital Partners emphasizes investing in companies with strong free cash flows, disciplined capital allocation, and high dividend growth for superior risk-adjusted returns [1] - The market has shifted towards AI leaders since late 2022, leading to the fund's underperformance due to narrow breadth, although there is a recent shift supported by the outperformance of dividend-focused indices [1] - The firm's Data Science team's advancements in the Distant Future Model present strong opportunities for investors to buy into the strategy and mitigate risks in a concentrated market [1] Company Highlights: Eli Lilly and Company - Eli Lilly and Company is highlighted as a leading contributor in the fourth-quarter 2025 investor letter, with a market capitalization of $786.041 billion [2] - The stock closed at $878.24 per share on March 27, 2026, with a one-month return of -13.73% and a 52-week gain of 6.34% [2] - Eli Lilly's incretin portfolio, particularly its GLP-1 franchise (Mounjaro and Zepbound), has led to significant market share gains, commanding 58% of the US incretin market and 71% of new prescriptions [3] - Management raised annual guidance for the third time in 2025, indicating strong performance expectations moving into 2026, especially with the anticipated launch of the oral GLP-1 drug (orforglipron) [3] - The oral alternative is expected to expand the market globally due to its ease of use, simpler supply chain, and lower cost [3]

From 4h ago09.21 BSTBrent crude on track for record monthly rise of nearly 60%Brent crude is on course for a record monthly rise of nearly 60%, exceeding gains it made during the 1990 Gulf War.The global oil benchmark is currently trading 3.5% higher at $116.051 a barrel – up 59% so far in March – while New York light crude rose 2% to $101.6 a barrel.Yemen’s Houthi rebels, which are backed by Iran, launched their first attacks on Israel since the start of the US-Israel war with Iran over the weekend. More U ...